drugset / Trial / NCT00942864

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

NCT00942864

Phase 3 Completed 40 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).

Timeline

Start
2008-12
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal